Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IDM-2101: Updated Phase II data

Updated data from an open-label Phase II trial in 63 evaluable patients showed that median survival times

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE